Experimental combo targets lung cancer that resists immunotherapy
NCT ID NCT04911166
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a combination of two treatments—atezolizumab (an immunotherapy drug) and interleukin-12 gene therapy (which uses a virus to deliver a gene that boosts the immune system)—in 13 people with advanced non-small cell lung cancer that had worsened after initial immunotherapy. The main goal was to see if the combination was safe and could shrink tumors or slow the disease. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab (an immunotherapy drug) combined with interleukin-12 gene therapy (a treatment that uses a virus to deliver a gene that boosts the immune system)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced lung cancer whose disease has worsened after initial immunotherapy.
What could go wrong
This was a very early (Phase I) trial that was terminated early, so results are limited. The combination may cause serious side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States